Understanding Your Prescription Weight Loss Options
What's Better Wegovy or Mounjaro for Prescription Weight Loss?
When considering what's better Wegovy or Mounjaro, the answer depends entirely on your individual circumstances rather than one treatment being universally superior. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, which works as a dual agonist targeting both GLP-1 and GIP receptors, potentially offering a different mechanism for weight management. Both are prescription-only medicines requiring clinical assessment and ongoing prescriber supervision. Your choice should be guided by factors including your medical history, current medications, lifestyle preferences, and how your body responds to treatment. At EverydayMeds, both options are available through our GPhC-registered pharmacy (#9012878) with comprehensive prescriber support.
The question of what's better Wegovy or Mounjaro often comes down to practical considerations alongside clinical factors. Wegovy follows a structured dose escalation from 0.25mg to 2.4mg maintenance over 16 weeks, with each step carefully designed to minimise side effects while optimising efficacy. Mounjaro has its own titration schedule starting at 2.5mg. Both treatments must be used alongside a reduced-calorie diet and increased physical activity as part of a comprehensive weight management approach. Neither should be viewed as a standalone solution, and both require long-term commitment as weight regain typically occurs when treatment stops. Your prescriber will consider your BMI, weight-related comorbidities, previous weight loss attempts, and personal preferences when recommending the most suitable option.
Prescription Weight Loss Pricing and Value Comparison
Understanding the costs involved helps answer what's better Wegovy or Mounjaro from a practical standpoint. Wegovy at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose (£209.99). New customers can apply code FIRST40 at checkout, while returning customers use code DOSE25 to reach these final prices. Our Getting Started bundles provide convenience for dose transitions, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio covering three consecutive doses for £369.99. These bundles ensure continuity of supply without the need for multiple orders, particularly important during the critical dose escalation phase.
When comparing what's better Wegovy or Mounjaro, consider that both require similar long-term investment as prescription-only medicines. The maintenance phase represents the ongoing cost commitment, with Wegovy's 2.4mg dose at £209.99 per month providing a clear pricing structure. Our Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99, ensuring treatment continuity without interruption. Remember that both treatments are investments in long-term health outcomes, potentially reducing future costs associated with weight-related comorbidities. The clinical assessment fee and ongoing prescriber monitoring are included in our service, providing comprehensive care rather than just medication supply. Your prescriber can discuss the expected treatment duration and total investment required for your specific weight management goals.
Clinical Evidence: Wegovy vs Mounjaro Weight Loss Trials
The clinical evidence helps inform what's better Wegovy or Mounjaro for individual patients, though direct head-to-head comparisons aren't available due to different trial designs and populations. In clinical trials, patients taking Wegovy alongside diet and exercise achieved average weight loss of approximately 15% at 68 weeks in the STEP 1 trial, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP programme demonstrated consistent results across different populations, with STEP 2 showing 9.6% average weight loss in patients with type 2 diabetes. These results represent averages from controlled clinical trials and individual responses may vary significantly.
When considering what's better Wegovy or Mounjaro, it's important to note that Mounjaro's weight loss trials used different methodologies, patient populations, and endpoints, making direct percentage comparisons inappropriate. Both treatments showed clinically meaningful weight loss in their respective trials when combined with lifestyle interventions. The SELECT cardiovascular outcomes trial demonstrated that Wegovy reduced major cardiovascular events by 20% in adults with established cardiovascular disease, adding an important safety and efficacy dimension beyond weight loss alone. Your prescriber will review the clinical evidence most relevant to your health profile when determining which treatment may be most suitable.
How Wegovy Works for Prescription Weight Loss
Understanding Wegovy's mechanism helps clarify what's better Wegovy or Mounjaro for your specific needs. Wegovy is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a natural hormone released by your intestines after eating. This hormone signals to your brain that you're full and satisfied, naturally reducing your desire to continue eating. By activating GLP-1 receptors, Wegovy slows gastric emptying, meaning food stays in your stomach longer, prolonging the feeling of fullness between meals. The treatment also influences the hypothalamus, the brain region controlling appetite and food cravings, potentially reducing the psychological drive to overeat. Unlike stimulant-based appetite suppressants, Wegovy works through your body's natural satiety pathways, supporting more sustainable eating pattern changes when combined with dietary modifications and increased physical activity.
Your Wegovy Ordering Process at EverydayMeds
Starting your prescription weight loss journey begins with our streamlined 3-minute online clinical assessment covering your medical history, current medications, previous weight loss attempts, and treatment goals. This comprehensive questionnaire ensures our UK-registered prescribers have all necessary information to make safe, appropriate treatment recommendations. Once submitted, expect prescriber review within 3 working days through our standard service, or upgrade to express 24-hour review for faster treatment initiation. Upon approval, your Wegovy prescription is dispensed from our GPhC-registered pharmacy (#9012878) and dispatched via temperature-controlled, cold-chain delivery to preserve medication integrity. Next-day delivery ensures you receive your treatment quickly while maintaining the 2-8°C storage requirements essential for medication stability and efficacy.
Storage and Practical Considerations
Practical storage differences may influence what's better Wegovy or Mounjaro for your lifestyle needs. Wegovy must be stored in the refrigerator at 2-8°C before first use, but offers superior travel convenience with 6 weeks of room temperature stability once removed from refrigeration (provided temperatures stay below 30°C). This extended room temperature window makes Wegovy particularly suitable for frequent travelers, business professionals, or anyone whose lifestyle requires medication flexibility. Mounjaro, in comparison, maintains stability for only 21 days at room temperature, requiring more careful planning for extended trips or situations where refrigeration isn't readily available. The Wegovy FlexTouch pre-filled pen delivers precise doses through simple dial-and-inject operation, with each pen containing four weekly doses. Proper injection technique training is provided with your first prescription, ensuring confident self-administration throughout your weight management journey.
Choosing Between Dual-Hormone and Single-Hormone Approaches
The fundamental difference when considering what's better Wegovy or Mounjaro lies in their hormonal mechanisms, with Wegovy targeting GLP-1 receptors exclusively while Mounjaro activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-hormone approach theoretically provides additional pathways for appetite control and metabolic regulation, though individual responses vary significantly between patients. Some prescribers prefer starting with single-hormone GLP-1 agonists like Wegovy to establish baseline response before considering dual-hormone alternatives if needed.
Your medical history, current medications, and specific health goals will guide this decision more than theoretical mechanisms. Patients with certain gastrointestinal sensitivities might respond differently to single versus dual-hormone approaches, while those with diabetes-related weight concerns may have different optimal pathways. The established clinical evidence base, longer market availability, and extensive real-world usage data for Wegovy provides additional confidence for many prescribers and patients. Both treatments require identical lifestyle commitments including reduced-calorie diets and increased physical activity, making mechanism of action just one factor in the overall treatment decision.
Start Your Prescription Weight Loss Journey Today
Rather than wondering what's better Wegovy or Mounjaro indefinitely, take the first step with our comprehensive clinical assessment that connects you directly with experienced UK prescribers. New customers can begin from £79.99 using code FIRST40 at checkout, while returning customers access the same pricing with code DOSE25. Both Wegovy and Mounjaro are available through EverydayMeds, ensuring you have access to expert guidance regardless of which treatment proves most suitable for your needs. Our clinical team provides ongoing support throughout your weight management journey, from initial dose escalation through long-term maintenance, adjusting treatment as needed based on your progress and any side effects experienced. Complete your assessment today at https://everydaymeds.co.uk/collections/wegovy and discover which prescription weight loss approach aligns with your health goals and lifestyle requirements.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
